Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

This is a multicentric, phase II and open label study.75 patients are expected to be randomized in 35 centers. The main objective is to assess the efficacy and safety of Afatinib -cetuximab combo versus cetuximab alone in treatment of patients with refractory wtKRAS metastatic colorectal cancer.

本研究为一项多中心、II期开放标签临床试验。计划在35家研究中心对75例患者实施随机分组。本研究的主要研究目标为评估阿法替尼(Afatinib)联合西妥昔单抗(cetuximab)对比单用西妥昔单抗，治疗难治性野生型KRAS(wtKRAS)转移性结直肠癌患者的疗效与安全性。